These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11387713)

  • 1. [Selective TNF-alpha inhibition in Crohn disease. Emergency help in problem cases].
    MMW Fortschr Med; 2001 May; 143(18):52. PubMed ID: 11387713
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
    MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
    [No Abstract]   [Full Text] [Related]  

  • 3. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing the risks and benefits of prolonged use of infliximab.
    Schölmerich J
    Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biological compounds in the treatment of Crohn's disease].
    Dinari G
    Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
    [No Abstract]   [Full Text] [Related]  

  • 6. [Practice guidelines in gastroenterology. Use of anti-TNF agents in inflammatory bowel disease. European guide 2001-2003].
    Rom J Gastroenterol; 2002 Mar; 11(1):68-71. PubMed ID: 12219731
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.
    Holtmann MH; Galle PR; Neurath MF
    Am J Gastroenterol; 2003 Feb; 98(2):504-5. PubMed ID: 12591081
    [No Abstract]   [Full Text] [Related]  

  • 8. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
    Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
    Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
    J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment.
    Núñez Martínez O; Ripoll Noiseux C; Carneros Martín JA; González Lara V; Gregorio Marañón HG
    Am J Gastroenterol; 2001 May; 96(5):1665-6. PubMed ID: 11374737
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.
    Zeissig S; Bojarski C; Buergel N; Mankertz J; Zeitz M; Fromm M; Schulzke JD
    Gut; 2004 Sep; 53(9):1295-302. PubMed ID: 15306588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease.
    Beltrán B; Nos P; Bastida G; Iborra M; Hoyos M; Ponce J
    Gut; 2006 Nov; 55(11):1670-1. PubMed ID: 17047119
    [No Abstract]   [Full Text] [Related]  

  • 14. Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg?
    Hollander D
    Am J Gastroenterol; 2002 Aug; 97(8):1867-8. PubMed ID: 12190145
    [No Abstract]   [Full Text] [Related]  

  • 15. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 16. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
    Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
    Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab in fistulizing Crohn's disease.
    Osterman MT; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):795-820. PubMed ID: 17129814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [When should anti-TNF-alpha treatment in Crohn disease be terminated?].
    Moum B
    Tidsskr Nor Laegeforen; 2010 Mar; 130(5):474. PubMed ID: 20224609
    [No Abstract]   [Full Text] [Related]  

  • 19. Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.
    Fanning SB; Chapman G; Yau Y; Leong RW
    J Gastroenterol Hepatol; 2010 Jan; 25(1):215. PubMed ID: 20136975
    [No Abstract]   [Full Text] [Related]  

  • 20. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.